United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2016_register
executive
2016-04-22
article
Prospective Grant of Exclusive License: The Development of Anti-CD70 Chimeric Antigen Receptors (CARs) for the Treatment of Chronic Myelogenous Leukemia
Notices
D09002ee1bdc1c54d
D09002ee1bdc1c5e3
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Dedalus Pharma, LLC (``Dedalus'') located in Maryland, USA.
81 FR 23737
https://www.govinfo.gov/app/details/FR-2016-04-22/2016-09324
2016-09324
fr22ap16-85
4140-01-P
https://www.govinfo.gov/app/details/FR-2016-04-22/2016-09324
https://www.govinfo.gov/content/pkg/FR-2016-04-22/html/2016-09324.htm
https://www.govinfo.gov/content/pkg/FR-2016-04-22/pdf/2016-09324.pdf
1 p.
23737
23737
81 FR 23737
Prospective Grant of Exclusive License: The Development of Anti-CD70 Chimeric Antigen Receptors (CARs) for the Treatment of Chronic Myelogenous Leukemia; Federal Register Vol. 81, Issue
NOTICE
2016-09324
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2016-05-09
4140-01-P
2016-09324
Notice.
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Dedalus Pharma, LLC (``Dedalus'') located in Maryland, USA.
Only written comments and/or applications for a license which are received by the Technology Transfer Center at the National Cancer Institute on or before May 9, 2016 will be considered.
Proposed Exclusive Licenses:
Development of Anti-CD70 Chimeric Antigen Receptors for the Treatment of Chronic Myelogenous Leukemia
,
andy.burke@nih.gov
Federal Register
Vol. 81, no. 78
Office of the Federal Register, National Archives and Records Administration
2016-04-22
continuing
daily
deposited
born digital
455 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2016-04-22
P0b002ee18f42d766
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr22ap16
https://www.govinfo.gov/app/details/FR-2016-04-22
https://www.govinfo.gov/content/pkg/FR-2016-04-22/pdf/FR-2016-04-22.pdf
https://www.govinfo.gov/content/pkg/FR-2016-04-22/xml/FR-2016-04-22.xml
fdlp
23563
24008
DGPO
2016-04-22
2023-04-29
FR-2016-04-22
machine generated
eng
FR
FR-2016-04-22
81
78